A Reaction Nine Days After Restarting Infliximab: What the Antibody Titer Actually Settles
Her Crohn’s has responded to infliximab for years. The question isn’t whether the drug works — it’s whether the reaction she just had means her body has already stopped letting it.
Camila R., a 34-year-old high school choir director, has managed Crohn's disease with infliximab for six years, well enough that she stopped thinking of herself as a patient with a chronic illness rather than someone who happens to take an infusion every two months. A five-month gap opened up this spring after an insurance lapse during a district budget dispute delayed her prior authorization; she restarted infliximab fifteen days ago at what her gastroenterologist intended as a routine re-induction dose. Nine days after that infusion — six days ago now — she developed a diffuse urticarial rash, fever to 38.6°C, and symmetric joint pain in both hands and knees severe enough that she could not conduct rehearsal standing up — the delayed, serum-sickness-like reaction pattern Cheifetz and colleagues characterized in patients retreated after a substantial gap in dosing, distinct from the acute infusion reactions that happen during or immediately after the drip itself.
The reaction resolved over four days with antihistamines and a short prednisone taper, leaving her symptom-free for the past two, but the question of what it means for continuing infliximab could not be answered from the bedside alone. An anti-infliximab antibody titer and infliximab trough level, drawn during the reaction and resulted two days later, came back with a high antibody titer and an undetectable trough — not simply confirmation that a reaction happened, but a specific signature of the drug being neutralized by her own immune system before it could reach a therapeutic level, the mechanistic finding that actually separates “a reaction occurred” from “the drug has already stopped working.” Her most recent colonoscopy, six weeks before the gap began, had shown mucosal healing — genuinely well-controlled disease, not a patient already trending toward flare when the interruption happened.
Restarting a drug her own labs say she may have already immunologically outrun is a different decision than restarting one that simply gave her a bad week, and that distinction is what the team actually has to resolve before her next scheduled infusion date arrives.
What the trough level actually changes
Six years of good control on this drug is real evidence, and I don't want to throw it away over one reaction with an identifiable cause — the gap. My instinct going in was to resume on a strict, uninterrupted schedule with premedication and never let another interruption happen.
I understand that instinct, and before the labs came back I might have agreed with it. But a high antibody titer with an undetectable trough isn't just 'she had a bad reaction' — it's a specific, measurable signal that her own immune system has already neutralized the drug before it reached therapeutic levels in her blood. That's a different problem than an infusion reaction we can premedicate around.
Premedicating treats the visible reaction. It does nothing about the fact that, per this trough, the drug may not actually be working anymore — continuing risks a worse reaction on top of a therapy that's already failed immunologically, not just a repeat of the same manageable one.
I agree the antibody data changes the calculus, but I'd anchor the final decision to something neither of you has emphasized yet: her colonoscopy six weeks ago showed mucosal healing. She wasn't trending toward flare when this gap happened — she was in genuine remission.
That matters because it means we're not choosing under time pressure from active disease. We can afford to switch her to a different mechanism now, cleanly, rather than gambling on whether premedication can outrun an antibody response her own labs already say is real.
Infliximab was discontinued and ustekinumab induction scheduled, timed to begin from her documented state of remission rather than waiting for any sign of clinical flare — the team's explicit choice to switch from a position of strength rather than reactively, once disease activity worsened.
Agreed by all three voices once the trough result was in hand: the antibody data, not the reaction itself, was what actually settled the decision — a milder reaction with a normal trough and low titer would very plausibly have supported the Gastroenterologist's original plan to resume with premedication, and everyone acknowledged that distinction explicitly rather than treating the outcome as inevitable from the first symptom.